retatrutide clinical results VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Phase 3: TRIUMPH Program

doi: 10.1016/s0167-0115(96)00113-9

[DOI] [PMC free article] [PubMed] [Google Scholar] 120.Passilly-Degrace P, Chevrot M, Bernard A, Ancel D, Martin C, Besnard P

Published phase 2 obesity trial details for retatrutide: New England Journal of Medicine trial

avoid excessive consumption of caffeinated or sugary beverages, which can exacerbate dehydration or affect blood glucose control

Boxes pre-printed with: Drug name & investigational status Dosage strength Lot number Safety warnings Proper packaging plays a critical role in ensuring: Product integrity Chain-of-custody transparency Accurate dosage identification Minimized risk of mix-ups and counterfeit substitution In the wider pharmaceutical sector, adapting packaging that supports regulatory standards is vital especially for high-interest compounds such as peptides and investigational injections

The material and conclusions contained in this document are for information purposes only and TransRe offers no guarantee for the completeness of its contents